Shaping the future of precision oncology
At ESMO 2026, Natera and collaborators are presenting 20+ abstracts and showcasing an expanded precision diagnostics portfolio, redefining how cancer is tracked at the molecular level.
Schedule meetingTrusted by clinicians, researchers, and drug developers worldwide
Leader in MRD
The definitive MRD portfolio with Signatera™, Latitude™, and Clarity™*1,2,3
Unmatched Clinical Footprint
500,000+ patients tested, ordered by more than 55% of US oncologists1
Global Development Partner
Regulatory infrastructure with FDA-approved, IVDR-certified, PMDA-approved MRD testing, proven in global pivotal studies2,3,†
Featured oral presentations
Explore 20+ abstractsAbstract: 542RO
Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1Presenter: Yukinori Ozaki
Oct 23, 2026, 16:15 - 17:45
Abstract: 4741RO
Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Patients With Muscle-Invasive Bladder Cancer From NIAGARAPresenter: Matthew D. Galsky
Oct 24, 2026, 10:15 - 11:45
Presenter: Kazuki Nozawa
Oct 26, 2026, 10:15 - 11:45
For Biopharma: New data from Natera's expanded diagnostics portfolio
Natera is expanding what's measurable across the full development journey with ultrasensitive MRD detection, tissue-free response monitoring, and comprehensive genomic profiling to support early development through commercial launch.*
Tumor-informed Ultrasensitive MRD
Signatera™ Genome
RUO + IUO
The only MRD assay to track PVs, SVs, and SNVs for the highest fidelity signal, demonstrating an analytical limit of detection (LOD95) below 1ppm tumor fraction and with ctDNA detected at levels below 0.1ppm3
Oct 25, 2026, 12:00–12:45 PM, #3542P
Read ESMO AbstractTissue-free MRD
Latitude™ PanTumor
RUO
Rapid and sensitive methylation-based ctDNA assay for response monitoring in metastatic settings and as a reflex from Signatera when tissue is unavailable
Oct 23, 2026, 15:15–16:00, #4276P
Read ESMO AbstractComprehensive Genomic Profiling
Altera™ Liquid
RUO + IUO
Plasma-based targeted panel of 523 genes. Stand-alone or sample-sparing add-on to any MRD test
Oct 23, 2026, 15:15–16:00, #4260P
Read ESMO AbstractHighlights of ESMO Abstracts
Explore 20+ abstracts redefining molecular-guided cancer management from diagnosis through survivorship.
Meet Danielle, breast cancer survivor and Signatera patient
Diagnosed with invasive ductal carcinoma, Danielle began Signatera ctDNA monitoring after her mastectomy. A positive result over a year into surveillance prompted an early treatment change by resuming hormone therapy and joining a newly available clinical trial option. Several consecutive negative Signatera tests later, Danielle is celebrating that she remains serially negative and cancer-free. Watch and learn more about Danielle's story.
Connect with us at ESMO 2026
Natera's integrated portfolio is built for the next generation of precision oncology. Meet our team at ESMO 2026 in Booth 1015 · Hall 10 or fill out the form to start the discussion.
References:
- *Research use only (RUO) and Investigational Use Only (IUO). Not yet available commercially for healthcare professionals
- †PMDA Approval Number: 30800BZI00018000. First EU IVDR for solid-tumor, tumor-informed ctDNA MRD
- 1.Natera internal data, as of July 2026.
- 2.Signatera™ CDx is an FDA-approved Companion Diagnostic test intended to identify Muscle Invasive Bladder Cancer (MIBC) patients with ctDNA MRD-positive status who may benefit from atezolizumab. For the approved intended use, product limitations and detailed performance characteristics, refer to FDA approved labeling under the PMA #P260004.
- 3.Analytical limit of detection demonstrated by Signatera Genome in a cell line dilution study. Signatera Genome with PVs and SVs available as a Research Use Only (RUO) assay, Natera internal data.